{"id":"NCT00776230","sponsor":"Valneva Austria GmbH","briefTitle":"Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling","officialTitle":"Immunogenicity of a Commercial Batch of the Japanese Encephalitis Vaccine IC51 up to Twenty-four Months Post Filling. An Open-label, Multicenter, Phase 3 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2010-06","completion":"2010-06","firstPosted":"2008-10-21","resultsPosted":"2014-01-23","lastUpdate":"2016-05-04"},"enrollment":304,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Japanese Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"IC51","otherNames":["Japanese Encephalitis vaccine"]}],"arms":[{"label":"IC51 (~12 months post filling)","type":"ACTIVE_COMPARATOR"},{"label":"IC51 (~18 months post filling)","type":"ACTIVE_COMPARATOR"},{"label":"IC51 (~24 months post filling)","type":"ACTIVE_COMPARATOR"}],"summary":"The objective is to assess immunogenicity of a commercial IC51 batch at 3 different time points post filling (12, 18, 24 months) in terms of Geometric Mean Titers (GMT) for anti-JEV neutralizing antibodies at Day 56 after the first vaccination.","primaryOutcome":{"measure":"Primary: 1. Geometric Mean Titers (GMT) at Day 56","timeFrame":"56 days post 1st vaccination","effectByArm":[{"arm":"IC51 Cohort 1","deltaMin":100.1,"sd":null},{"arm":"IC51 Cohort 2","deltaMin":84.7,"sd":null},{"arm":"IC51 Cohort 3","deltaMin":68.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":3,"countries":["Austria","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":98},"commonTop":["Headache","Influenza Like Illness","Fatigue","Nasopharyngitis","Myalgia"]}}